Affinity Maturation of a Potent Family of HIV Antibodies Is Primarily Focused on Accommodating or Avoiding Glycans.

PubWeight™: 1.18‹?› | Rank: Top 10%

🔗 View Article (PMID 26682982)

Published in Immunity on December 15, 2015

Authors

Fernando Garces1, Jeong Hyun Lee1, Natalia de Val1, Alba Torrents de la Pena2, Leopold Kong1, Cristina Puchades3, Yuanzi Hua3, Robyn L Stanfield1, Dennis R Burton4, John P Moore5, Rogier W Sanders6, Andrew B Ward1, Ian A Wilson7

Author Affiliations

1: Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA; International AIDS Vaccine Initiative Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA; Scripps Center for HIV/AIDS Vaccine Immunology & Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA.
2: Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, Amsterdam, 1105 AZ, the Netherlands.
3: Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
4: International AIDS Vaccine Initiative Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA; Scripps Center for HIV/AIDS Vaccine Immunology & Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
5: Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, NY 10065, USA.
6: Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, Amsterdam, 1105 AZ, the Netherlands; Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, NY 10065, USA.
7: Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA; International AIDS Vaccine Initiative Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA; Scripps Center for HIV/AIDS Vaccine Immunology & Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA; Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA. Electronic address: wilson@scripps.edu.

Articles citing this

Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice. Cell (2016) 1.57

Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer. Science (2016) 1.36

HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies. Immunity (2016) 1.26

Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein. Cell Rep (2016) 1.05

Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. Proc Natl Acad Sci U S A (2016) 0.93

Uncleaved prefusion-optimized gp140 trimers derived from analysis of HIV-1 envelope metastability. Nat Commun (2016) 0.92

Holes in the Glycan Shield of the Native HIV Envelope Are a Target of Trimer-Elicited Neutralizing Antibodies. Cell Rep (2016) 0.88

Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site. Nat Struct Mol Biol (2016) 0.88

Progress toward active or passive HIV-1 vaccination. J Exp Med (2016) 0.86

Structural basis for germline antibody recognition of HIV-1 immunogens. Elife (2016) 0.84

Sequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C. PLoS Pathog (2016) 0.84

Cryo-EM structure of a CD4-bound open HIV-1 envelope trimer reveals structural rearrangements of the gp120 V1V2 loop. Proc Natl Acad Sci U S A (2016) 0.83

Native-like Env trimers as a platform for HIV-1 vaccine design. Immunol Rev (2017) 0.83

An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability. Nat Microbiol (2016) 0.82

Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development. Immunol Rev (2017) 0.82

Quaternary contact in the initial interaction of CD4 with the HIV-1 envelope trimer. Nat Struct Mol Biol (2017) 0.79

The HIV-1 envelope glycoprotein structure: nailing down a moving target. Immunol Rev (2017) 0.79

Mechanisms of escape from the PGT128 family of anti-HIV broadly neutralizing antibodies. Retrovirology (2016) 0.78

Structure-Based Design of a Soluble Prefusion-Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity. J Virol (2017) 0.78

HIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds. Retrovirology (2016) 0.77

Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodies. Sci Transl Med (2017) 0.76

Ontogeny-based immunogens for the induction of V2-directed HIV broadly neutralizing antibodies. Immunol Rev (2017) 0.76

Somatic Hypermutation-Induced Changes in the Structure and Dynamics of HIV-1 Broadly Neutralizing Antibodies. Structure (2016) 0.76

Stabilized HIV-1 envelope glycoprotein trimers for vaccine use. Curr Opin HIV AIDS (2017) 0.76

Genetic and structural analyses of affinity maturation in the humoral response to HIV-1. Immunol Rev (2017) 0.76

Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies. Immunol Rev (2017) 0.76

Evolution of B cell analysis and Env trimer redesign. Immunol Rev (2017) 0.76

Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation. Cell Rep (2017) 0.76

HIV-1 Escape from a Peptidic Anchor Inhibitor through Stabilization of the Envelope Glycoprotein Spike. J Virol (2016) 0.75

A non-canonical binding interface in the crystal structure of HIV-1 gp120 core in complex with CD4. Sci Rep (2017) 0.75

Global site-specific N-glycosylation analysis of HIV envelope glycoprotein. Nat Commun (2017) 0.75

Recognition of HIV-Inactivating Peptide Triazoles by the Recombinant Soluble Env Trimer, BG505 SOSIP.664. Proteins (2017) 0.75

Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates. Cell Rep (2017) 0.75

Survivors Remorse: antibody-mediated protection against HIV-1. Immunol Rev (2017) 0.75

Exploring human antimicrobial antibody responses on a single B cell level. Clin Vaccine Immunol (2017) 0.75

Tyrosine-sulfated V2 peptides inhibit HIV-1 infection via coreceptor mimicry. EBioMedicine (2016) 0.75

Stabilized HIV-1 envelope glycoprotein trimers for vaccine use. Curr Opin HIV AIDS (2017) 0.75

Differential Antibody Responses to Conserved HIV-1 Neutralizing Epitopes in the Context of Multivalent Scaffolds and Native-Like gp140 Trimers. MBio (2017) 0.75

Co-operation between strain-specific and broadly neutralizing responses limited viral escape, and prolonged exposure of the broadly neutralizing epitope. J Virol (2017) 0.75

Structure and topology around the cleavage site regulate post-translational cleavage of the HIV-1 gp160 signal peptide. Elife (2017) 0.75

Env-Specific Antibodies in Chronic Infection versus in Vaccination. Front Immunol (2017) 0.75

Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo. J Exp Med (2017) 0.75

Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop. Immunity (2017) 0.75

High-throughput Protein Engineering Improves the Antigenicity and Stability of Soluble HIV-1 Envelope Glycoprotein SOSIP Trimers. J Virol (2017) 0.75

How HIV-1 entry mechanism and broadly neutralizing antibodies guide structure-based vaccine design. Curr Opin HIV AIDS (2017) 0.75

Improving the Immunogenicity of Native-like HIV-1 Envelope Trimers by Hyperstabilization. Cell Rep (2017) 0.75

Articles cited by this

Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr (2004) 227.01

PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr (2010) 108.52

EMAN: semiautomated software for high-resolution single-particle reconstructions. J Struct Biol (1999) 27.52

A new generation of the IMAGIC image processing system. J Struct Biol (1996) 12.57

VARIATIONS IN AFFINITIES OF ANTIBODIES DURING THE IMMUNE RESPONSE. Biochemistry (1964) 11.48

Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature (2011) 11.07

Automated molecular microscopy: the new Leginon system. J Struct Biol (2005) 10.00

Complete nucleotide sequences of functional clones of the AIDS virus. AIDS Res Hum Retroviruses (1987) 7.85

Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol (2008) 7.14

Appion: an integrated, database-driven pipeline to facilitate EM image processing. J Struct Biol (2009) 5.71

Maturation of the immune response in germinal centers. Cell (1991) 5.68

Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science (2013) 5.53

Generation of antibody diversity in the immune response of BALB/c mice to influenza virus hemagglutinin. Proc Natl Acad Sci U S A (1984) 5.49

A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science (2011) 5.44

Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science (2013) 4.61

Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science (2009) 4.20

Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J Virol (2008) 3.83

DoG Picker and TiltPicker: software tools to facilitate particle selection in single particle electron microscopy. J Struct Biol (2009) 3.71

Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature (2014) 3.50

Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc Natl Acad Sci U S A (2012) 3.33

Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat Struct Mol Biol (2013) 3.11

Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog (2013) 2.66

Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies. Cell (2014) 2.27

A clustering approach to multireference alignment of single-particle projections in electron microscopy. J Struct Biol (2010) 2.19

Antibody responses to envelope glycoproteins in HIV-1 infection. Nat Immunol (2015) 1.82

The effects of somatic hypermutation on neutralization and binding in the PGT121 family of broadly neutralizing HIV antibodies. PLoS Pathog (2013) 1.67

Rapid development of broadly influenza neutralizing antibodies through redundant mutations. Nature (2014) 1.65

The effect of antigen dose and time after immunization on the amount and affinity of anti-hapten antibody. J Immunol (1968) 1.61

Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV. Sci Transl Med (2014) 1.60

Accessing the Kabat antibody sequence database by computer. Proteins (1996) 1.54

Structural evolution of glycan recognition by a family of potent HIV antibodies. Cell (2014) 1.28

Insights into the trimeric HIV-1 envelope glycoprotein structure. Trends Biochem Sci (2015) 1.10